WHO says anything short of full trial disclosure skews public spending

By Gareth Macdonald

- Last updated on GMT

Related tags Medicine Health care

WHO calls for Full trial disclosure
WHO calls for Full trial disclosure
Drug, vaccine and medical device developers should publish all trial results according to the WHO, which says anything less skews R&D priorities and public healthcare investment.

World Health Organisation (WHO) Assistant Director General for Health Systems and Innovation Marie-Paule Kieny called for greater disclosure today​, arguing that full disclosure "underpins the principal goal of medical research: to serve the betterment of humanity.​”

Failure to publicly disclose trial results engenders misinformation, leading to skewed priorities for both R&D and public health interventions​” said Kieny, adding "it creates indirect costs for public and private entities, including patients themselves, who pay for suboptimal or harmful treatments.​”

Last month a report in the New England Journal of Medicine (NEJM) revealed that the vast majority​ of results from clinical trials are not reported on ClinicalTrials.gov within a year of their ending.

An earlier study​ of vaccine trials registered in various databases revealed that full results from only 29% had been published in a peer-reviewed journal within 24 months of completion, which is the target timescale the WHO recommends.

Trial registry

In 2005 the WHO called for unambiguous identification of all interventional clinical trials and established the International Clinical Trials Registry Platform, which collates information on trials that have been notified in a network of clinical trial registries.

The WHO's comments fit with those of the US Institute of Medicine (IOM)​, UK politicians​, Ben Goldacre's Alltrials​ organisation.

Members of the European parliament passed a law​ designed to force drugmakers to publish clinical trial results this time last year.

The European Medicines Agency (EMA) already hosts a trial database​, however the agency has not yet decided how the additional information required by the new legislation​ will be made public​.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars